FDA
-
-
-
-
-
-
-
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
-
-
-
-
-
-
-
INmune Bio expands CORDStrom platform collaboration with Anthony Nolan
-
-
-
-
-
-
-
INmune Bio reports 2025 financial results, plans regulatory filings
-
-
-
-
-
-
-
INmune Bio receives FDA alignment on phase 2b/3 trial design for alzheimer's drug
-
-
-
-
-
-
-
INmune Bio presents new imaging data for Alzheimer's drug at CTAD conference
-
-
-
-
-
-
-
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
-
-
-
-
-
-
-
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
-
322,876 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

